Neogen Chemicals Limited reported a 67% year-on-year surge in consolidated net profit to ₹17 crore for the quarter ended June 30, 2026 (Q1FY27), driven by record revenues in its Organolithium portfolio and robust performance from its battery materials subsidiary, Neogen Ionics Limited. Consolidated revenue from operations rose 34% to ₹250 crore, while EBITDA jumped 53% to ₹48 crore. The strong financial performance was achieved despite ongoing headwinds from the Dahej plant reconstruction, higher working capital intensity, and geopolitical freight spikes.

The Board of Directors approved the unaudited financial results on July 26, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and recommended by Statutory Auditors Chandabhoy & Jassoobhoy. Additionally, the Board approved raising up to ₹600 crore through a Qualified Institutional Placement (QIP), subject to shareholder and statutory approvals.

Financial Performance

Consolidated revenue reached ₹250 crore in Q1FY27, compared to ₹184.60 crore in Q1FY26. Gross profit expanded by 37% to ₹117 crore. EBITDA grew significantly by 53% to ₹48 crore, reflecting favorable product mix and cost pass-through mechanisms implemented to protect margins against rising raw material and input costs. Net profit after tax (PAT) increased by 67% to ₹17 crore. Consolidated earnings per share (EPS) stood at ₹6.29 per share.

On a standalone basis, revenue rose 37% to ₹252.30 crore, with net profit increasing 37% to ₹19.44 crore. Standalone EBITDA was ₹48.20 crore, up 39% year-on-year, with margins expanding by 30 basis points to 19.1%. Interest expenses increased by 65% to ₹23.10 crore, attributed to higher debt servicing costs following recent credit rating adjustments and increased borrowing to fund capital expenditure.

Neogen Ionics Limited contributed significantly to the group’s growth, with revenue reaching ₹19 crore in Q1FY27, compared to ₹5 crore in the same period last year. This represents over 50% of the subsidiary’s entire prior-year revenue generated in a single quarter.

Expansion Initiatives and Strategic Outlook

Neogen Chemicals is accelerating its footprint in the lithium-ion battery sector through Neogen Ionics Limited. The company has commissioned 200 MTPA capacity for lithium electrolyte salts and additives, with first approval material shipped to customers. Trial production is ongoing for the remaining 1,300 MTPA. A new 1,000 MTPA capacity is targeted for commissioning in H2 FY27, alongside an additional 500 MT intermediate capacity. The 2,000 MT electrolyte plant at Dahej is fully commissioned.

The total estimated project cost for Neogen Ionics’ Dahej Phase 1 and Pakhajan Phase 2 projects stands at ₹1,795 crore. Of this, ₹218 crore was incurred in Q1FY27, bringing cumulative expenditure to ₹1,298 crore. Dahej Phase 1, budgeted at ₹428 crore, is targeted for completion by February 2027, while Pakhajan Phase 2, budgeted at ₹1,367 crore, is expected to be ready by March 2027. Morita’s $20 million equity contribution toward the joint venture remains committed.

What the Numbers Show

The divergence between standalone and consolidated metrics highlights the strategic pivot toward battery materials. While standalone operations delivered steady growth, the consolidated EBITDA surge of 53% versus standalone’s 39% indicates that high-margin contributions from Neogen Ionics are beginning to offset the transitional costs at the core chemical business. The 65% rise in interest expenses underscores the leverage required to fund this aggressive expansion, making the timely execution of the QIP crucial for maintaining balance sheet health. With the Dahej plant reconstruction complete and trial runs underway, the normalization of core operations combined with scaling battery materials output positions the company for significant operating leverage in FY27.

Neogen Chemicals has received approval to raise ₹6 billion through a Qualified Institutional Placement (QIP), marking a significant capital-raising milestone for the specialty chemicals company.

Capital Raise Details

The following table outlines the key details of the approved fundraising initiative:

About the QIP Route

A Qualified Institutional Placement is a capital-raising mechanism that enables listed companies to issue equity shares or securities to qualified institutional buyers. This route is widely used by Indian-listed companies as it offers a relatively faster and more streamlined process for raising funds compared to other public offering methods, without requiring a separate prospectus filing with the market regulator.

Neogen Chemicals' approval to raise ₹6 billion through this instrument underscores the company's intent to access institutional capital markets for its funding requirements.